A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs NIS 793 (Primary) ; PDR 001 (Primary)
- Indications Breast cancer; Colorectal cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Nov 2017 Planned number of patients changed from 154 to 160.
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.